Circulation, Vol 70, 599-605, Copyright © 1984 by American Heart Association
Y Yui, R Hattori, Y Takatsu, H Nakajima, A Wakabayashi, C Kawai, N Kayama, S Hiraku, T Inagawa and M Tsubojima
The effect of the selective thromboxane A2 synthetase inhibitor OKY- 1581,
a pyridine derivative [sodium (E)-3-(4-(3-pyridylmethyl)phenyl)-2-
methyl-2-propenoate], on thromboxane B2 and 6-keto-prostaglandin F1 alpha
levels and platelet aggregation was studied in human volunteers. To clarify
its effectiveness as an enzyme inhibitor, OKY-1581, at doses of 17, 83,
167, 417, 833, and 1667 micrograms/kg (n = 5 for each group), was injected
intravenously, or was infused (10 micrograms/kg/min; n = 5) over 3 hr on 3
successive days. OKY-1580 (OKY- 1581 free acid) was rapidly converted to
its main beta-oxidized product, OKY-1565, and its reduced form, OKY-1558.
During the study, plasma thromboxane B2 levels, inhibition of thromboxane
B2 production in serum, and inhibition of rabbit platelet thromboxane A2
synthetase were monitored continuously. Twenty-five minutes after the
injection of the above doses, plasma thromboxane B2 levels decreased by 4
+/- 7%, 40 +/- 14%, 57 +/- 7%, 68 +/- 6%, 93 +/- 5%, and 96 +/- 5% (mean
+/- SD), respectively. Thromboxane B2 production in serum was decreased by
2 +/- 8%, 70 +/- 10%, 75 +/- 8%, 81 +/- 10%, and 96 +/- 8%, respectively,
and rabbit platelet thromboxane A2 synthetase by 2 +/- 7%, 52 +/- 8%, 79
+/- 10%, 80 +/- 9%, 96 +/- 8%, and 95 +/- 7%. These parameters returned to
the control levels 24 hr after the injection.(ABSTRACT TRUNCATED AT 250
WORDS)
ARTICLES
Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1984 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |